OBIO
Orchestra BioMed Holdings, Inc.
Next earnings Aug 3, 2026 · consensus $-0.40 EPS, $124K rev
$4.24
▲ +8.72%$4.24▲ +36.77%
over 1Y
L $2.35EODHDH $5.35
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.7%
1W+3.9%
1M+7.3%
3M-0.5%
YTD-1.6%
1Y+36.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 1169.2% YoY; but unprofitable (net margin -157.4%).
Revenue (FY2025) $33.5M · FY2025
Orchestra BioMed Holdings, Inc. shows $33.5M in FY2025 revenue (+1169.2% YoY), a -157.4% net margin, and -98.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $3.53M | $2.76M | $2.64M | $33.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$395K | -$32.7M | -$51.5M | -$64.3M | -$51.8M |
| Net income | -$379K | -$33.6M | -$49.1M | -$61.0M | -$52.7M |
| Diluted EPS | -$0.02 | -$2.24 | -$1.48 | -$1.66 | -$1.11 |
| Net margin | — | -951.3% | -1779.7% | -2313.3% | -157.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$228M
EV / EBITDA—
EV / Sales6.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-21.2%
FCF yield-19.9%
Quality & risk
ROIC (est.)-59.7%
Free cash flow-$49.5M
Total debt$15.0M
Net cash$19.7M
Altman Z-Score-1.77 distress
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+52.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗8-KPeriod ending 2026-06-232026-06-23open ↗S-8Filing2026-06-23open ↗DEFA14AFiling2026-06-16open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-012026-06-02open ↗
Frequently asked
- Is Orchestra BioMed Holdings, Inc. (OBIO) a buy?
- OBIO currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 1169.2% YoY; but unprofitable (net margin -157.4%).
- What is Orchestra BioMed Holdings, Inc.'s quality score?
- OBIO scores 54.41176470588235/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001814114, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:19:00 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.